Novo Nordisk (NVO) plans to launch its blockbuster weight-loss drug Wegovy in vial format. The move targets customers who have shifted to rival Eli Lilly & Co. (LLY).
This packaging change follows Eli Lilly’s lead in offering similar options for obesity treatments. Novo Nordisk currently distributes Wegovy exclusively through plastic injector pens.
The update aims to broaden accessibility and boost competitiveness in the growing market for weight management drugs.
Icahn Enterprises L.P. (NASDAQ: IEP) disclosed its first-quarter 2026 financial results, posting a net loss attributable to the company of…
Boxing fans are gearing up for an explosive showdown as Teofimo Lopez defends his WBO super lightweight title against undefeated…
Mitsubishi Gas Chemical Company, Inc. released its fiscal year 2025 third quarter results presentation, highlighting a net loss amid impairment…
OverviewGoldman Sachs BDC (GSBD) trades at a record 28.6% discount to net asset value (NAV), marking its deepest valuation gap…
